‹
›
This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
The Beacon
Pembrolizumab in First Line Clear Cell RCC & the Evolving Role of Immunotherapy in Metastatic RCC: Highlights from ASCO 2018 (BMIC-053)
30
00:00:00
/ 00:03:19
30